
[Skip to Content](#)

[Calendar](#) | [For Your Patients](#) | [PHA Main Site](#) | [Contact Us](#) | [About Us](#) | Not a registered user? [Sign up here.](#)

Member Login:

[Forgot Password?](#) | [Register for an Account](#)

- [Courses](#)
 - [New Course Releases](#)
 - [Browse All Courses](#)
- [Advances in PH Journal](#)
 - [About the Journal](#)
 - [Journal Archives](#)
 - [Editorial Advisory Board](#)
 - [Instructions for Authors](#)
- [Resource Library](#)
 - [PHA Presentations](#)
 - [PHA Partner Presentations](#)
 - [Upcoming Webinars](#)
 - [Webinar Archives](#)
 - [Browse All Recordings](#)
 - [PH Learning Modules](#)
 - [History of PH](#)

-
- [Peer-Reviewed Journals](#)
 - [PHA Publication Resources](#)
 - [Books](#)
 - [En Español](#)
 - [Diagnosis & Treatment](#)
 - [About PH](#)
 - [Diagnosis Algorithm](#)
 - [Early Diagnosis](#)
 - [Associated Diseases](#)
 - [Insurance & SSD](#)
 - [Treatment Fact Sheets](#)
 - [Practice Resources](#)
 - [Consensus Statements](#)
 - [Research](#)
 - [PH Research Abstracts](#)
 - [PHA's Research Program](#)
 - [PHA Research Room](#)
 - [PH Clinical Trials](#)
 - [Other PH Research Programs](#)
 - [Networking](#)
 - [Upcoming Events](#)
 - [Medical Membership Networks](#)
 - [Find a Colleague](#)

In This Section

- [About the Journal](#)
- [Journal Archives](#)
- [Editorial Advisory Board](#)
- [Instructions for Authors](#)

Advances in PH Journal

[Home](#) » [Advances in PH Journal](#)

//

Reviews

[Sign in](#) to add a review

[0 comments](#)

[Leave a Comment](#)

[Tweet](#) !function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0];if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src="//platform.twitter.com/widgets.js";fjs.parentNode.insertBefore(js,fjs);}}(document,"script","twitter-wjs");

```
(function(d, s, id) { var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) return; js = d.createElement(s); js.id = id; js.src =
"//connect.facebook.net/en_US/all.js#xfbml=1"; fjs.parentNode.insertBefore(js, fjs);
})(document, 'script', 'facebook-jssdk');
```

[Vol 11, No 3 \(Fall 2012\)](#)

[Download This Issue](#)

While most issues of *Advances in Pulmonary Hypertension* provide up to 2 hours of CME credit, because credit was available at the 10th International Pulmonary Hypertension Conference and Scientific Sessions, this issue does not offer credit. To test your understanding of the material in this issue, you may quiz yourself using the questions below. Check your answers using the link at the bottom of this page. Watch for CME opportunities in future issues of *Advances*.

1. Which of the following represents an important risk factor for pulmonary hypertension in the developing world?

- a. High-altitude resistance
- b. Infectious diseases (HIV, parasites, bacteria)
- c. Heart disease

d. COPD

e. All of the above

2. Hereditary hemorrhagic telangiectasia associated PAH may involve which of the following cell signaling pathways?

a. TGFb

b. Activin-like kinase 1

c. Nitric oxide

d. Both a and b

e. a, b, and c

3. The percentage of patients with BMPR2 mutations in idiopathic PAH is estimated to be approximately:

a. 6%

b. 20%

c. 50%

d. 70%

4. The Warburg effect is seen when cells preferentially use glycolysis over glucose oxidation as a source of cellular energy.

a. True

b. False

5. PPAR_α (proliferating peroxisome) activation is used to treat insulin resistance and may provide a new therapeutic modality for PAH by:

a. Lowering blood glucose

b. Restoring normal BMPR2 signaling

c. Weight loss

d. Inhibiting endothelin-1 signaling

6. In humans with PAH, metabolic changes have been observed including which of the following:

a. Decreased oxidative stress

-
- b. Insulin resistance
 - c. Hypoglycemia
 - d. None of the above

7. High fat diets increase the penetrance of PAH in BMPR2 mutant mice or the development of PAH in apolipoprotein E deficient mice:

- a. True
- b. False

8. The total number of patients with BMPR2 mutations is highest in which group of patients:

- a. Idiopathic PAH
- b. Heritable PAH
- c. Associated PAH
- d. PVOD

9. The DNA-repair enzyme, poly-ADP-ribose polymerases (PARP), is activated in PAH cells with enhanced proliferation and survival:

- a. True
- b. False

[Check Your Answers](#)

[PREVIOUS](#) * [NEXT](#)

[Log In to Comment](#)

Comments

Related Resources

- [Ascertainment of Pulmonary Arterial Hypertension \(FPAH\) Families with Numerous Affected Members](#)
- [Chasing the Pulmonary Hypertension Gene: What Have We Caught?](#)
- [Chasing Pulmonary Hypertension](#)
- [Summary of Pulmonary Hypertension Genetics and Genomics](#)
- [The Future of Genetics in Pulmonary Arterial Hypertension](#)

- [Site Map](#)
- [Site Feedback](#)
- [Privacy Policy](#)

Charles Burger, MD

Immediate Past Editor, Advances in Pulmonary Hypertension, Mayo Clinic Florida-Jacksonville, Fla.

© 2017 Pulmonary Hypertension Association.
801 Roeder Road, Ste. 1000, Silver Spring, MD 20910
301-565-3004 | PHAOnlineUniv@PHAssociation.org